ArticleACS infectious diseases2024
Tambjamines as Fast-Acting Multistage Antimalarials.
Abstract read
In one paragraph
Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Potent acridone antimalarial against all three life stages of Plasmodium.Nature communications · 2026Article
- Tambjamines as Promising Leads for the Development of Next-Generation Antifungals againstACS medicinal chemistry letters · 2026Article
- Acridone Prodrugs with Enhanced Dual-Stage Antimalarial Efficacy.ACS medicinal chemistry letters · 2025Article
- Optimization of Tambjamines Active against Multiple Stages of Malaria Parasites.Journal of medicinal chemistry · 2025Article
- Development of Next-Generation Antimalarial Acridones with Radical Cure Potential.Journal of medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Amrendra KumarDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.
Yuexin LiDepartment of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
Rozalia A DodeanDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID 0000-0001-5002-4607
Alison RothExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Diana CaridhaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Michael S MadejczykExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Xiannu JinExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
William E DennisExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Patricia J LeeExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Brandon S PybusExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Monica MartinExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Kristina PannoneExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Hieu T DinhExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Cameron BlountExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Ravi ChetreeExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Jesse DeLucaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Martin EvansExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Robert NadeauExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Chau VuongExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Susan LeedExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Chad BlackExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Jason SousaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Christina NolanExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Frida G CejaDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States.
Stephanie A RasmussenDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States.
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Central Region, Uganda.
Philip J RosenthalDepartment of Medicine, University of California San Francisco, San Francisco, California 94143, United States.
Roland A CooperDepartment of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California 94901, United States.
Matthias RottmannDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Kreuzstrasse 2, CH-4123 Allschwil, Switzerland.
Pamela Orjuela-SanchezDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States.
Stephan MeisterDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States.
Elizabeth A WinzelerDepartment of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-4049-2113
Michael J DelvesDepartment of Life Science, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom.ORCID 0000-0001-8526-4782
Holly MatthewsDepartment of Life Science, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom.
Jake BaumDepartment of Life Science, Imperial College London, South Kensington, London SW7 2AZ, United Kingdom.
Robert W KirbyMetrion Biosciences Ltd., Granta Park, Cambridge CB21 6AL, United Kingdom.
Jeremy N BurrowsMMV Medicines for Malaria Venture, Geneva, CH-1215 Geneva, Switzerland.ORCID 0000-0001-8448-6068
James DuffyMMV Medicines for Malaria Venture, Geneva, CH-1215 Geneva, Switzerland.
David H PeytonDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID 0000-0001-5828-055X
Kevin A ReynoldsDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID 0000-0003-0270-9809
Jane X KellyDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID 0000-0001-8871-0207
Papireddy KancharlaDepartment of Chemistry, Portland State University, Portland, Oregon 97201, United States.ORCID 0000-0002-6381-1236
Funding
Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4MMechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3MNovel Multiple-Stage Active AntimalarialsR01AI141972 · NIAID · PORTLAND STATE UNIVERSITY · PI JANE X KELLY, Papireddy Kancharla · 2019 to 2026
$4.5MNatural Product Inspired Novel Antimalarials with Radical Cure PotentialR01AI175444 · NIAID · PORTLAND STATE UNIVERSITY · PI JANE X KELLY, Papireddy Kancharla · 2023 to 2026
$2.5MResistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618kNIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI139179NIAID NIH HHS R01 AI141972NIAID NIH HHS R01 AI175444NIAID NIH HHS R56 AI075045Wellcome TrustWellcome Trust 100993/Z/13/Z
Abstract
Well-tolerated and novel antimalarials that can combat multiple stages of the parasite life cycle are desirable but challenging to discover and develop. Herein, we report results for natural product-inspired novel tambjamine antimalarials. We show that they are potent against liver, asexual erythrocytic, and sexual erythrocytic parasite life cycle stages. Notably, our lead candidate
Indexed as
AntimalarialsMalariaPlasmodium falciparumAnimalsDisease Models, AnimalErythrocytesHumansLife Cycle StagesMalaria, FalciparumMiceMice, Inbred NODMice, SCIDPlasmodium yoeliiAntimalarialsantimalarialsantiplasmodialfast-actingmultistagenatural productstambjamines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.